<DOC>
	<DOCNO>NCT00483925</DOCNO>
	<brief_summary>Langerhans-cell histiocytosis ( LCH ) rare disease feature chronic inflammation hypopituitarism , condition associate increase risk cardiovascular disease . Objective : To investigate glucose lipid metabolism , insulin resistance , structural arterial functional endothelial property patient multisystem LCH prospective , observational study . Interventions : Cardiovascular risk factor : arterial blood pressure , lipid profile , mathematical index insulin resistance ( IR ) , intima medium thickness , brachial artery flow mediate dilatation , dynamic index IR , pituitary function C-reactive protein estimate patient LCH control group match gender , age , BMI smoke habit .</brief_summary>
	<brief_title>Cardiovascular Risk Factors LCH Adults</brief_title>
	<detailed_description>CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS : EVIDENCE OF ABNORMALITIES OF CARBOHYDRATE METABOLISM Langerhans cell histiocytosis ( LCH ) rare disease , usually affect child although recently increasingly recognize adult prevalence approximately 1/560.000 case ( , ) . LCH characterize aberrant proliferation dendritic cell monocyte-macrophage system resemble normal epidermal Langerhans ’ cell . These cell infiltrate many site body lead either localized lesion widespread systemic disease . Although LCH show clonal disorder ( ) also exhibit feature inflammatory disease , alter expression cytokine cellular adhesion molecule important migration home Langerhans cell document ( , ) . In addition , LCH show particular predilection hypothalamo-pituitary axis ( HPA ) involvement lead diabetes insipidus and/ anterior pituitary dysfunction 15–50 % 5–20 % , patient respectively ( 3 , , , ) . These percentage may higher adult patient multisystem involvement , 94 % 59 % respectively ( ) . The ongoing inflammatory process presence hypopituitarism consider two independent risk factor cardiovascular disease probably induction insulin resistance ( IR ) ( , , ) . The various therapy use treatment multisystem LCH , chemotherapy , radiotherapy particularly glucocorticoid , may also adversely affect cardiovascular system mostly IR ( , ) . It therefore possible patient LCH represent group high risk cardiovascular disease additive effect number different contribute mechanism know induce IR . Insulin resistance besides produce adverse metabolic profile also lead endothelial dysfunction early vascular disease ( ) . Early vascular disease detect non-invasive surrogate marker , intima-media thickness ( IMT ) vascular structure property flow-mediated vasodilatation ( FMD ) vascular functional property ( , , ) . Carotid IMT consider establish marker early atherosclerotic disease predictor future cardiovascular event ( 16 ) whereas brachial artery FMD correlate coronary endothelial function , well-known predictor future cardiovascular event ( 18 ) . Main outcome measure : Cardiovascular risk factor assessment estimate patient LCH compare control ; effect hypopituitarism , disease activity and/ treatment determine . SUBJECTS AND METHODS All patient fulfil diagnostic criterion “ definitive diagnosis ” LCH ( ) . Matched sex , age , BMI healthy individual , good health receive medication know affect carbohydrate , sex hormone metabolism , and/or endothelial function least 3 month prior also recruit study . Clinical data patient well hormonal imaging assessment register . All subject participate strenuous physical activity balance isocaloric diet least 4 week prior study . Current smoker ask smoke one day hemodynamic study . Cardiovascular risk factor assessment : Clinical cardiovascular risk : - BMI - waist circumference - systolic ( SBP ) diastolic ( DBP ) blood pressure Metabolic Profile The metabolic study patient perform 10h overnight fasting : - Oral glucose tolerance test - Glucose , insulin - Total cholesterol , HDL-cholesterol , triglycerides - Indices Insulin resistance [ GIR ( ) , HOMA ( ) , QUICKI ( ) , MATSUDA ( ) , glucose insulin response glucose calculate area curve ( AUC ) OGTT performance glucose ( AUCGLU ) insulin ( AUCINS ) , use trapezoidal rule , predict index first phase insulin secretion , predict index second phase insulin secretion ( ) ] . Hemodynamic study - The hemodynamic study perform , day metabolic study . Both functional structural arterial property assess non-invasive , easily reproducible hemodynamic ultrasonographic method , namely : IMT measurement carotid arteries endothelium-dependent FMD endothelium-independent nitrate-induced dilatation ( NID ) measurement brachial artery . IMT , FMD NID measure B-Mode high-resolution ultrasound imaging ( VIVID PRO ; GENERAL ELECTRIC ) ( ) . - Arterial stiffness assess Applanation Tonometry ( SphygmocorTM PWV MEDICAL ) radial artery . Inflammatory index C-reactive protein ( CRP ) measurement . References Baumgartner I , von Hochstetter A , Baumert B , Luetolf U , Follath F 1997 Med Pediatr Oncol 28:9-14 - Dunger DB , Broadbent V , Yeoman E , Seckl JR , Lightman SL , Grant DB , Pritchard J 1989 The frequency natural history diabetes insipidus child Langerhans-cell histiocytosis N Engl J Med 321:1157-1162 - Willman CL , Busque L , Griffith BB , Favara BE , McClain KL , Duncan MH , Gilliland DG 1994 Langerhans'-cell histiocytosis ( histiocytosis X ) -- clonal proliferative disease N Engl J Med 331:154-160 - de Graaf JH , Tamminga RY , Dam-Meiring A , Kamps WA , Timens W 1996 The presence cytokine Langerhans ' cell histiocytosis J Pathol 180:400-40 - Egeler RM , Favara BE , van Meurs M , Laman JD , Claassen E 1999 Differential In situ cytokine profile Langerhans-like cell T cell Langerhans cell histiocytosis : abundant expression cytokine relevant disease treatment Blood 94:4195-4201 - Malpas JS 1998 Langerhans cell histiocytosis adult Hematol Oncol Clin North Am 12:259-26 - Willis B , Ablin A , Weinberg V , Zoger S , Wara WM , Matthay KK 1996 Disease course late sequela Langerhans ' cell histiocytosis : 25-year experience University California , San Francisco J Clin Oncol 14:2073-2082 - Grois NG , Favara BE , Mostbeck GH , Prayer D 1998 Central nervous system disease Langerhans cell histiocytosis Hematol Oncol Clin North Am 12:287-305 - Makras P , Samara C , Antoniou M , Zetos A , Papadogias D , Nikolakopoulou Z , Andreakos E , Toloumis G , Kontogeorgos G , Piaditis G , Kaltsas GA 2006 Evolving radiological feature hypothalamo-pituitary lesion adult patient Langerhans cell histiocytosis ( LCH ) Neuroradiology 48:37-44 - Alexander RW 1994 Inflammation coronary artery disease N Engl J Med . 1994 Aug 18 ; 331 ( 7 ) :468-9 - Rosen T , Bengtsson BA 1990 Premature mortality due cardiovascular disease hypopituitarism Lancet 336:285-288 - Wilson PW , Kannel WB , Silbershatz H , D'Agostino RB 1999 Clustering metabolic factor coronary heart disease Arch Intern Med 159:1104-1109 - Wei L , MacDonald TM , Walker BR 2004 Taking glucocorticoid prescription associate subsequent cardiovascular disease Ann Intern Med 141:764-770 - Andrews RC , Walker BR 1999 Glucocorticoids insulin resistance : old hormone , new target . Clin Sci ( Lond ) 96:513-523 W Wheatcroft SB , Williams IL , Shah AM , Kearney MT 2003 Pathophysiological implication insulin resistance vascular endothelial function Diabet Med 20:255-268 Hodis HN , Mack WJ , LaBree L , Selzer RH , Liu CR , Liu CH , Azen SP 1998 The role carotid arterial intima-media thickness predict clinical coronary event . Ann Intern Med 128:262-269 Schachinger V , Britten MB , Zeiher AM 2000 Prognostic impact coronary vasodilator dysfunction adverse long-term outcome coronary heart disease . Circulation 101:1899-1906 Anderson TJ , Uehata A , Gerhard MD , Meredith IT , Knab S , Delagrange D , Lieberman EH , Ganz P , Creager MA , Yeung AC , et al 1995 Close relation endothelial function human coronary peripheral circulation J Am Coll Cardiol 26:1235-1241 Arico M , Girschikofsky M , Genereau T , Klersy C , McClain K , Grois N , Emile JF , Lukina E , De Juli E , Danesino C 2003 Langerhans cell histiocytosis adult . Report International Registry Histiocyte Society Eur J Cancer 39:2341-2348 Legro RS , Finegood D , Dunaif A 1998 A fast glucose insulin ratio useful measure insulin sensitivity woman polycystic ovary syndrome J Clin Endocrinol Metab 83:2694-2698 Bergman RN , Prager R , Volund A , Olefsky JM 1987 Equivalence insulin sensitivity index man derive minimal model method euglycemic glucose clamp J Clin Invest 79:790-800 Katz A , Nambi SS , Mather K , Baron AD , Follmann DA , Sullivan G , Quon MJ 2000 Quantitative insulin sensitivity check index : simple , accurate method assess insulin sensitivity human J Clin Endocrinol Metab 85:2402-2410 Matsuda M , DeFronzo RA 1999 Insulin sensitivity index obtain oral glucose tolerance test . Comparison euglycemic insulin clamp Diabetes Care 22:1462-1470 Stumvoll M , Mitrakou A , Pimenta W , Jenssen T , Yki-Jarvinen H , Van Haeften T , Renn W , Gerich J Use oral glucose tolerance test ass insulin release insulin sensitivity Diabetes Care 295–301 Alexandraki K , Protogerou A , Papaioannou TG , Piperi C , Mastorakos G , Lekakis J , Panidis D , Diamanti-Kandarakis E 2006 Early Microvascular Macrovascular Dysfunction Accompanied Structural Injury Polycystic Ovary Syndrome . HORMONES ( Athens Greece ) 5:126-136</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<criteria>diagnostic criterion “ definitive diagnosis ” LCH participate strenuous physical activity , balance isocaloric diet least 4 week prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Langerhans cell histiocytosis</keyword>
	<keyword>flow mediate dilatation</keyword>
	<keyword>intima medium thickness</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>hypopituitarism</keyword>
	<keyword>glucose lipid metabolism ,</keyword>
	<keyword>structural arterial functional endothelial property patient multisystem LCH</keyword>
</DOC>